PMHNP Exam 2026/2027 | 169 Questions & Answers | Psychopharmacology, Bipolar Disorder, Schizophrenia, ECT, Substance Use & Psychiatric Nursing

This PMHNP Exam 2026/2027 study resource contains approximately 169 exam questions and answers across 41 pages, designed for intensive Psychiatric-Mental Health Nurse Practitioner review. The document covers high-yield areas including psychodynamic theory, Peplau’s psychiatric nursing theory, evidence-based practice, neurotransmitters, psychopharmacology, neuroleptic malignant syndrome, serotonin syndrome, catatonia, bipolar disorder, schizophrenia, depression, personality disorders, substance use disorders, ECT, therapeutic communication, sleep disorders, psychiatric emergencies, legal and ethical practice, ADHD and neurological disorders. The document itself does not identify a university or course code, so these details have not been fabricated for the title. The opening questions establish important foundations in psychiatric nursing theory and evidence-based practice. Topics include psychodynamic concepts such as defense mechanisms, transference and countertransference; the Transtheoretical Model of Behavior Change; Hildegard Peplau’s contribution to psychiatric nursing; the PICO model; evidence-based practice; resilience; concordance; and culturally competent care. Later questions return to Peplau’s Theory of Interpersonal Relations, including nursing roles, phases of the therapeutic relationship and levels of anxiety. A substantial portion focuses on neurobiology and psychiatric pharmacology. Questions address serotonin, dopamine, norepinephrine, monoamine neurotransmitters, catecholamines, agonists and antipsychotic potency. Students also review serious medication-related syndromes, particularly neuroleptic malignant syndrome and serotonin syndrome, including their clinical presentations, differential considerations and pharmacologic management as presented in the source. Catatonia is examined through DSM-5-TR criteria, laboratory findings and clinical subtypes such as retarded catatonia. The bipolar disorder and mood-disorder material includes acute hypomania and mania, mixed features, lithium therapy, lithium toxicity and medication interactions. The guide also addresses the HLA-B*1502 allele and carbamazepine, electroconvulsive therapy considerations, bipolar versus unipolar depression, geriatric bipolar disorder and the clinical recognition of hypomanic episodes. Depression-related questions extend into treatment approaches, complementary therapies, transcranial magnetic stimulation and vagal nerve stimulation. The schizophrenia section examines positive and negative symptoms, deficit schizophrenia, neurological soft signs, metabolic disturbances, schizophreniform disorder, treatment resistance, clozapine and ANC monitoring. Other psychotic-spectrum material includes persecutory delusions, delusions of parasitosis and differentiating primary psychiatric presentations from conditions that may suggest another etiology. Suicide risk among patients with schizophrenia is also addressed later in the document. Students receive extensive exposure to antidepressant pharmacology, including SNRIs, MAO-A, monoamine oxidase inhibitors, tyramine-related dietary restrictions, selegiline, mirtazapine, bupropion and cyclic antidepressants. The questions also explore SSRI-associated sexual dysfunction and specific antidepressant characteristics such as sedation, receptor affinity and antipsychotic effects. The resource includes clinical scenarios involving illness anxiety disorder, conversion disorder, acute delirium, violent behavior, synthetic drug intoxication, rhabdomyolysis, synthetic cathinone overdose and anticholinergic poisoning. These scenario-based questions require students to connect presenting symptoms, vital signs and laboratory findings with likely psychiatric or toxicological conditions. Another important section addresses psychiatric law, ethics and healthcare regulation, including HIPAA, FERPA, adolescent confidentiality, conscience clauses, psychiatric advance directives, incidental disclosure of protected health information, patient grievances, CMS restraint and seclusion requirements and competency requirements for staff caring for restrained patients. Hospital-Based Inpatient Psychiatric Services core measures and organizational just culture are also included. The guide reviews therapeutic communication and the therapeutic relationship, including simple reflections, normalizing and Shawn Shea’s transitional “gates.” It also addresses sleep efficiency, insomnia, ramelteon, narcolepsy, hormonal influences on sleep and obstructive sleep apnea. These topics broaden preparation beyond medication memorization into communication, assessment and behavioral-health management. Substance-use content is particularly extensive. Questions cover alcohol intoxication and withdrawal, Wernicke-Korsakoff syndrome, thiamine, chlordiazepoxide/Librium, disulfiram, naltrexone, benzodiazepine overdose, GHB intoxication and withdrawal, opioid use disorder, methadone and buprenorphine. The document also discusses the ASAM continuum of substance-use treatment and methadone-associated QTc concerns. Additional psychiatric and neurological material includes personality disorders, binge-eating disorder, psychogenic nonepileptic seizures, Lewy body dementia, Parkinson’s disease, OCD, EMDR, PANDAS, postpartum psychosis, Wilson’s disease, Kayser-Fleischer rings, photic-induced seizures, Lesch-Nyhan syndrome, Sydenham chorea, tardive dyskinesia, tardive dystonia, neuroferritinopathy, primary progressive aphasia and adult ADHD. The final section also examines assertive community treatment and further indications and considerations surrounding ECT. This material is particularly relevant for PMHNP students, Psychiatric-Mental Health Nurse Practitioner certification candidates, MSN-PMHNP students, DNP-PMHNP students, advanced practice psychiatric nursing students, graduate psychiatric nursing students, psychopharmacology students, mental health nursing students and learners preparing for psychiatric nursing or PMHNP board-style examinations. Because this is a third-party question-and-answer study document, medication doses, diagnostic statements and clinical recommendations should be cross-checked against current authoritative clinical references when used beyond exam review. Keywords: PMHNP Exam , PMHNP exam questions and answers, PMHNP practice questions, PMHNP exam prep, psychiatric mental health nurse practitioner, PMHNP board review, psychiatric nursing questions, psychopharmacology exam, bipolar disorder questions, schizophrenia questions, neuroleptic malignant syndrome, serotonin syndrome, catatonia, lithium toxicity, lithium monitoring, clozapine monitoring, ANC monitoring, antidepressants, antipsychotics, neurotransmitters, psychiatric medications, electroconvulsive therapy, ECT questions, substance use disorder, alcohol withdrawal, opioid use disorder, methadone, buprenorphine, psychiatric emergencies, therapeutic communication, Peplau theory, evidence based practice, PICO model, personality disorders, anxiety disorders, obsessive compulsive disorder, PANDAS, sleep disorders, HIPAA psychiatric nursing, psychiatric restraints, mental health assessment, adult ADHD, psychiatric nurse practitioner study guide